drugset
drugset / Trial / NCT01300260

Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose

NCT01300260 ↗

Phase 1 Completed 32 enrolled Eli Lilly and Company
RandomizedCrossoverTriple-blindTreatment

Summary

The purpose of this study is to measure the effect of LY2189265 to increase insulin levels in response to glucose intake.

Timeline

Start
2011-02
Primary completion
2011-08
Completion
2011-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Dulaglutide Peptide 1.5 mg Subcutaneous
Background Glucagon Peptide 1 mg Intravenous
Background Glucose Unknown 0.3 g/kg Intravenous
Background Glucose Unknown 15 g Intravenous
Background Glucose Unknown 20 g Intravenous
Background Glucose Unknown 25 g Intravenous
Background Insulin Protein / enzyme biologic — Intravenous

Indications

type 2 diabetes mellitus